Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05782270

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Anticoagulation Coronary Endarterectomy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100037, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.
  • No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.
  • Must be able to swallow tablets after the surgery.

Exclusion criteria

  • Patients with high bleeding risk (HAS-BLED ≥ 3);
  • Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time;
  • Emergency surgery;
  • Serum creatinine >130μmol/L, or significant liver dysfunction (elevated ALT and/or AST);
  • History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding;
  • History of hemorrhagic stroke, or platelet dysfunction;
  • Allergic or with contraindication to any of aspirin, clopidogrel or warfarin;
  • Participated in other clinical trial for drug or device within 30 days;
  • Pregnant or planning to be pregnant.

Treatment and study plan

Warfarin

Drug

dual antiplatelet therapy combined with warfarin

DAPT

Drug

Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)

CE+CABG

Other

Coronary endarterectomy combined with coronary artery bypass grafting

Primary outcomes

  1. Rate of coronary endarterectomy-targeted graft patency.

    Time frame: 6 months postoperatively

    Defined as less than 50% stenosis of the coronary endarterectomy target and coronary endarterectomy-targeted graft evaluated through either of coronary computed tomography angiography or coronary angiography.

Secondary outcomes

  1. Number of patients suffering from major adverse cardiovascular and cerebrovascular events

    Time frame: During 6-month follow-up

    Major adverse cardiovascular and cerebrovascular events is defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

  2. Bleeding events

    Time frame: during 6-month follow-up

    The Bleeding Academic Research Consortium (BARC) scale type 2~5 [see in reference].

Study contacts

Contact information is provided by the study sponsor or research team.

Xieraili Tiemuerniyazi, M.D.

CONTACT

[email protected]

010-88322265

Sponsors and collaborators

Lead sponsor

China National Center for Cardiovascular Diseases

Other Gov

Registry information

Official study title

Comparison of Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Mar 23, 2023
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.